Combinations, in context.

1998 human report: 120 ulcer patients and 30 healthy-reference donors; 1995 comparative rat study.

Reported results: T-cell indices reportedly moved toward reference values, while one subset index was unchanged. No numerical clinical healing effect or verified combined-treatment arm was supplied.

The 1995 experiment compared preparations, and the 1998 abstract does not resolve simultaneous use. Separate wound/cell studies are not combination replications. No formal synergy or validated human protocol.

2021 original fracture paper; eight rats per assay group, day 10, local intraosseous exposure.

Reported results: Phagocytic index 54.6±5.1% versus 30.8±3.1% in fracture controls; activation index 1.8±0.1 versus 0.4±0.03. Table marks p<0.05 versus fracture controls; no formal interaction test.

Thymogen is not Thymalin. Table symbols compare with fracture and uninjured controls, not pair versus each peptide alone. Surrogate assays do not establish human bone healing or clinical synergy.

Two overlapping Russian patent disclosures with six athletes per arm per sport.

Reported results: Day 21 cycling duration 8.4±0.2 vs 4.6±0.5 min (A + B vs saline). The earlier filing largely repeats the B and saline series.

No verified randomization or formal synergy test. Distinct from PPK-V; doses and preparations differ.

Krushinskaya dissertation and related journal record.

Reported results: Rat hemorrhage mortality 23% with pretreatment versus 79% in control (p<0.025 reported).

Preclinical pretreatment. Separate hemorrhage and hypoxia dosing; no evidence of human rescue efficacy.

2025 primary animal report.

Animal findings only. No single-component arms in the abstract; neither synergy nor human Parkinson disease benefit is established.

2005 clinical report and 2004 animal study.

Clinical sample size and allocation require full text. Animal additive effects cannot establish human synergy or attribute the clinical result to Bemitil alone.

2014 macrophage assays and 2015 rat inflammation experiments.

Experimental evidence only. Concentration-dependent biochemical effects do not establish clinical respiratory benefit or a safe human combination.

Separate 2006 animal studies; findings depend on the experimental setting.

In the swimming comparison, individual drugs performed better and longer than the combination. A separate heat experiment reported a favorable combination effect. Neither establishes universal synergy, a safe human ratio or heat protection in people.

Rostov research papers, 1995 and 1999; neurotransmitter and membrane endpoints.

Animal evidence only. Hyperoxia is not hypoxia; formal synergy and human benefit are not established. Not a recommended sleep or occupational regimen.

Zhumasheva 2009 experimental program; reviewed by Shabanov and colleagues in 2014.

Animal disease models, not human performance or pneumonia treatment evidence. Review is not independent replication. Distinct from B-300.

Elistratov dissertation, 2012; separate from Shustov’s earlier proposals.

Higher exposure was associated with more operator errors in the dissertation conclusions. Full allocation and safety appraisal incomplete. Not Binavit, not a validated field regimen.

Kim reports task-dependent results and ratio-sensitive animal interactions.

The monograph describes eight groups and two administrations during a six-hour workload. Allocation was based on equivalent baseline groups; randomization is not established. No piracetam-only arm, so synergy is not demonstrated.

Shustov’s proposed selection framework.

Alternatives, not an instruction to combine every listed substance. The 2019 book links Tomerzol to etomerzol; the preparation in this earlier framework still requires confirmation.

Shustov’s proposed task distinction.

Not an individually validated regimen.

Formulation and archival identifiers in Shustov’s abstract.

Component contributions and contemporary safety remain unassessed.

Kim’s dissertation conclusions.

Task-specific historical findings; not a treatment or return-to-duty guide.

Kim’s dissertation conclusions.

Names vary in transcription; complete methods require checking.

1996 guidance describes this pair.

Guidance is not proof of safe exposure. No extrapolation to H₂S or benzene; never a substitute for exposure controls or emergency care. The 1993 abstract has a monoxide/dioxide wording inconsistency requiring original-methods review.

Shustov’s cooling studies.

Separate alternatives; not a validated modern field protocol.

A linked 2012 clinical abstract reports combination use.

Related research, not attributed to Shustov. The abstract does not isolate either component.

Public post describes only two data points.

Not a Shustov-validated triple combination or a controlled study. See the linked field note.

2015 naval teaching proposal.

Underlying trial data absent from the passage; not contemporary treatment guidance.

2015 naval teaching proposal.

Underlying trial data absent from the passage; not contemporary treatment guidance.

2014 volunteer comparison with hypoxen and placebo.

Abstract does not describe isolated-component arms; no synergy, safe regimen or altitude-illness prevention conclusion.

Shustov’s 1996 author’s abstract explicitly lists Picamilon in its proposed selection framework.

Proposal, not a validated Bemitil–Picamilon pair or all-component stack. Sevan vessel involvement in the broader program does not establish Picamilon use aboard ship. Kim’s piracetam combinations are separate research.

Cherkashin 2003 dissertation excerpts; related to the Gazprom research program.

Not a Shustov regimen or a universal Gazprom worker protocol. Full methods pending; no modern synthetic-peptide equivalence or industrial hazard protection established.

RU2674342C2 animal experiments; related program, not attributed to Shustov.

Patent-reported combination findings; incomplete sleep recovery. No isolated-component efficacy, human benefit or safe-use regimen established.

EA005383B1, filed 2001 and published 2005; cites the 1999 Novikov–Shustov document.

Patent proposal without a comparative cohort; not a validated personal or occupational regimen.

2012 rat paw-inflammation study.

Animal findings do not establish human benefit or combination safety. This is not a Hypoxen–Bemitil performance trial.

PVS VMF-2002, Part II, Order 506.

Historical guidance, not a controlled combination trial or current poisoning-treatment advice.